Clinical trials: Anthracycline-induced Cardiotoxicity
Newly Diagnosed Acute Myeloid Leukemia (AML)
Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients
The aim of this study is to evaluate and compare the cardiotoxic effects associated with anthracycline-based induction chemotherapy and those receiving a Venetoclax or HMA regimens after four cycles of chemotherpy in patients…
- Trial name
- AML/HMA (NCT07851012)
- Volunteers
- 146 people
- Sponsor
- Assiut University
Breast Cancer, Cardiotoxicity
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.
- Trial name
- SAFE (NCT02236806)
- Testing
- Bisoprolol, Ramipril
- Where
- Italy
- Volunteers
- 262 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Cardiotoxicity, Cardiac Rehabilitation
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in…
- Trial name
- ONCORE (NCT03964142)
- Testing
- Cardiac rehabilitation
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Lymphoma, Heart Failure, Congestive
Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function…
- Trial name
- NCT00195897
- Where
- 2 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Henri Becquerel
Cardiotoxicity, Childhood Cancer
Prediction of Delayed Toxic Cardiomyopathy in Children
Longitudinal analysis of myocardial function using "Speckle Tracking Echocardiography" STE analysis and prediction of delayed toxic induced cardiomyopathy in young patients who received anthracycline therapy in childhood.
- Trial name
- SpeckleAnthra2 (NCT05781672)
- Testing
- cardiac ultrasound with speckle tracking analysis
- Where
- France
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Breast Cancer Female
Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients
According to the European Society of Cardiology 2022, the primary prevention of cancer therapyrelated cardiovascular toxicity during anthracycline chemotherapy include renin-angiotensin- aldosterone system blockers…
- Trial name
- NCT06703593
- Testing
- Alpha lipoic acid
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- British University In Egypt
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG
Management of patients with lymphoma is based on the administration of a chemotherapy containing anthracyclines (ATC), and allows cure rates of 65% to 80% at 5 years.
- Trial name
- DETECT (NCT04892667)
- Testing
- Intervention
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiomyopathies, Chemotherapy Effect
Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
Anthracyclines are one of the most well-known and effective drugs used to treat malignancies.The most important limiting factor in the use of this drug is its cardiac toxicity which includes cardiomyopathy and congestive heart…
- Conditions
- Cardiomyopathies, Chemotherapy Effect, Diastolic Dysfunction, Systolic Dysfunction
- Trial name
- NCT05175066
- Testing
- Bisoprolol
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Cardiomyopathy Due to Drug
Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity
This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment
- Trial name
- NCT06331806
- Testing
- Evaluation of myocardial fibrosis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European Institute of Oncology
Acute Myeloid Leukemia, Adult, Cardiotoxicity
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of…
- Conditions
- Acute Myeloid Leukemia, Adult, Cardiotoxicity, Endothelial Dysfunction
- Trial name
- NCT05703126
- Testing
- History taking, Anthropometry, Complete blood count
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Samara State Medical University
Neoplasms
Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity
Prospective single arm study to evaluate a low-dose CT-based protocol for early detection of myocardial dysfunction in 50 cancer patients undergoing anthracycline-based chemotherapy.
- Trial name
- NCT03553654
- Testing
- low dose CT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, San Diego
Heart Failure
Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy
Breast cancer is very common and afflicts 1 in 9 North American women. The treatment of breast cancer often requires the use of chemotherapy including "anthracyclines".
- Trial name
- NCT00247975
- Testing
- L-carnitine
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy.
- Trial name
- NCT00003070
- Testing
- enalapril maleate, quality-of-life assessment
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 13 people
- Sponsor
- Children's Oncology Group
Childhood Cancer
Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity
Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cancer…
- Trial name
- NCT04036045
- Testing
- Cardiac MRI, Echocardiogram, Blood Draw
- Where
- United States
- Sponsor
- Connecticut Children's Medical Center
Patients With Cancer
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
- Trial name
- NCT04030546
- Testing
- Ivabradine
- Where
- Lithuania
- Volunteers
- 128 people
- Sponsor
- Vilnius University
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases
Breast Cancer
Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
- Trial name
- NCT06491680
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Helwan University